Clinical trials dosing

Amiodarone adsorbs to polyvinyl chloride (PVC) tubing, and the clinical trial dose administration schedule was designed to account for this adsorption. Clinical trials were conducted using PVC tubing therefore its use is recommended. The concentrations and rates of infusion provided in Administration and Dosage reflect doses identified in these studies. It is important that the recommended infusion regimen be followed closely. 

Scanning electron micrograph showing continuous endothelial cell coverage of the stent struts after five-day implantation (preclinical study of clinical trial dose BiodivYsio Batimastat Stent). 

Note. CTD specification established for larger vessel clinical trials (i.e., BRILLIANT-EU) and the actual measured dose for the animal study dose is within this CTD range. aThese samples were produced using a less concentrated drug solution to achieve a dose lower than clinical trial dose. 

Abbreviations-. AS. added support BRILLIANT-EU. batimastat (BB94) anti-restenosis trial utilizing the BiodivYsio local drug delivery FC-stent CTD. clinical trial dose OC, open cell. 

The SNAC/heparin combination has been evaluated in phase I and phase II clinical trials. Furthermore, in phase I clinical trials dosing insulin in combination with SNAC a rapid elevation of plasma insulin and a subsequent decrease in plasma glucose levels were observed. In a phase II clinical trial in patients with type 2 diabetes, insulin was orally administered in combination with SNAC and metformin failing to achieve significant superior glycemic control over treatment with metformin alone (Hoffman and Qadri 2008). 

Adults oral doses of 20 to 40 mg every 4 hours or 30-60 mg every 6 to 8 hours not to exceed 180 mg daily. Long-acting preparation 60 mg twice a day. The extended-release oral Polistirex suspension delivers dextromethorphan from an ion-exchange complex over a period of 9 to 12 hours. One 60-mg dose of Pohstirex suspension dehvers a plasma concentration similar to two 30-mg doses of immediate-release dextromethorphan given every 6 hours. For preemptive surgical pain control doses between 90 and 120 mg have been used in different clinical trials. Doses employed for control of neuropathic pain are considerably higher (200-300 mg) as tolerated. 

Cromakalim. Cromakalim has along half-life (254). Cromakalim at an oral dose of 1.5 mg ia humans significantly lowers blood pressure 19/12 mm Hg (systohc/diastoHc pressure). It iacreases reaal blood flow, PRA, and heart rate. Cromakalim has bronchodilating activity that is beneficial for hypertensive asthmatic patients. Because of some undesirable effects seen ia cardiac papillary muscles of animals oa long-term treatmeat, future clinical trials are to be carried out usiag the active enantiomer, lemakalim (BRL 38227). 

For ISIS 301012, a second-generation antisense inhibitor of apoB-100 in November 2006. Isis announced results from two Phase 2 clinical trials of ISIS 301012. In the first study repotted, patients with high cholesterol on stable doses of statins were treated with ISIS 301012 for 5 weeks. Patients who received 300 mg/week of ISIS 301012 in this study achieved a 51% reduction in LDL-cholesterol (LDL), a 42% reduction in total cholesterol (TC), and a 4l% reduction in triglycerides (TG) beyond the levels achieved with statins alone. 

Vertex also put in clinical trial VX-765, another caspase-1 -specific, YVAD-derived peptidomimetic that is in vitro slightly more potent then pralnacasan (IC50 0.8 nM). Evaluation of VX-765 in a mouse model of oxazolone-induced dermatitis showed a dose-dependent (10-100 mg/kg) inhibition of ear inflammation. Consequently, VX-765 was enrolled in a 4-week phase Ila safety and pharmacokinetic study for psoriasis. However, Vertex has not communicated any results yet. 

---